-
Je něco špatně v tomto záznamu ?
Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease
D. Vinereanu, A. Wang, H. Mulder, RD. Lopes, P. Jansky, BS. Lewis, BJ. Gersh, A. Avezum, M. Hanna, C. Held, L. Wallentin, CB. Granger, JH. Alexander,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu srovnávací studie, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 1996-01-01 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1996-01-01 do Před 3 měsíci
- MeSH
- antikoagulancia terapeutické užití MeSH
- aortální chlopeň * MeSH
- cévní mozková příhoda epidemiologie prevence a kontrola MeSH
- fibrilace síní komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- mitrální chlopeň * MeSH
- nemoci srdečních chlopní komplikace MeSH
- pyrazoly terapeutické užití MeSH
- pyridony terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- warfarin terapeutické užití MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
OBJECTIVE: To assess stroke/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. METHODS: There were 14 793 patients with known VHD status, categorised as having moderate or severe mitral regurgitation (MR) (n=3382), aortic regurgitation (AR) (n=842) or aortic stenosis (AS) (n=324); patients with moderate or severe mitral stenosis were excluded from the trial. Baseline characteristics, efficacy and safety outcomes were compared between each type and no significant VHD. Treatment effect was assessed using an adjusted model. RESULTS: Patients with MR or AR had similar rates of stroke/systemic embolism and bleeding compared with patients without MR or AR, respectively. Patients with AS had significantly higher event rates (presented as rate per 100 patient-years of follow-up) of stroke/systemic embolism (3.47 vs 1.36; adjusted HR (adjHR) 2.21, 95% CI 1.35 to 3.63), death (8.30 vs 3.53; adjHR 1.92, 95% CI 1.41 to 2.61), major bleeding (5.31 vs 2.53; adjHR 1.80, 95% CI 1.19 to 2.75) and intracranial bleeding (1.29 vs 0.51; adjHR 2.54, 95% CI 1.08 to 5.96) than patients without AS. The superiority of apixaban over warfarin on stroke/systemic embolism was similar in patients with versus without MR (HR 0.69, 95% CI 0.46 to 1.04 vs HR 0.79, 95% CI 0.63 to 1.00; interaction P value 0.52), with versus without AR (HR 0.57, 95% CI 0.27 to 1.20 vs HR 0.78, 95% CI 0.63 to 0.96; interaction P value 0.52), and with versus without AS (HR 0.44, 95% CI 0.17 to 1.13 vs HR 0.79, 95% CI 0.64 to 0.97; interaction P value 0.19). For each of the primary and secondary efficacy and safety outcomes, there was no evidence of a different effect of apixaban over warfarin in patients with any VHD subcategory. CONCLUSIONS: In anticoagulated patients with AF, AS is associated with a higher risk of stroke/systemic embolism, bleeding and death. The efficacy and safety benefits of apixaban compared with warfarin were consistent, regardless of presence of MR, AR or AS. CLINICAL TRIAL REGISTRATION: ARISTOTLE clinical trial number NCT00412984.
Bristol Myers Squibb Princeton New Jersey USA
Dante Pazzanese Institute São Paulo University São Paulo Brazil
Duke Clinical Research Institute Duke University School of Medicine Durham North Carolina USA
Lady Davis Carmel Medical Center Haifa Israel
Mayo Clinic Rochester Minnesota USA
University Hospital Motol Prague Czech Republic
Uppsala Clinical Research Center Uppsala University Uppsala Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012902
- 003
- CZ-PrNML
- 005
- 20190411133321.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/heartjnl-2017-312272 $2 doi
- 035 __
- $a (PubMed)29352007
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vinereanu, Dragos $u Cardiology, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania. Cardiology, University and Emergency Hospital, Bucharest, Romania.
- 245 10
- $a Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease / $c D. Vinereanu, A. Wang, H. Mulder, RD. Lopes, P. Jansky, BS. Lewis, BJ. Gersh, A. Avezum, M. Hanna, C. Held, L. Wallentin, CB. Granger, JH. Alexander,
- 520 9_
- $a OBJECTIVE: To assess stroke/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. METHODS: There were 14 793 patients with known VHD status, categorised as having moderate or severe mitral regurgitation (MR) (n=3382), aortic regurgitation (AR) (n=842) or aortic stenosis (AS) (n=324); patients with moderate or severe mitral stenosis were excluded from the trial. Baseline characteristics, efficacy and safety outcomes were compared between each type and no significant VHD. Treatment effect was assessed using an adjusted model. RESULTS: Patients with MR or AR had similar rates of stroke/systemic embolism and bleeding compared with patients without MR or AR, respectively. Patients with AS had significantly higher event rates (presented as rate per 100 patient-years of follow-up) of stroke/systemic embolism (3.47 vs 1.36; adjusted HR (adjHR) 2.21, 95% CI 1.35 to 3.63), death (8.30 vs 3.53; adjHR 1.92, 95% CI 1.41 to 2.61), major bleeding (5.31 vs 2.53; adjHR 1.80, 95% CI 1.19 to 2.75) and intracranial bleeding (1.29 vs 0.51; adjHR 2.54, 95% CI 1.08 to 5.96) than patients without AS. The superiority of apixaban over warfarin on stroke/systemic embolism was similar in patients with versus without MR (HR 0.69, 95% CI 0.46 to 1.04 vs HR 0.79, 95% CI 0.63 to 1.00; interaction P value 0.52), with versus without AR (HR 0.57, 95% CI 0.27 to 1.20 vs HR 0.78, 95% CI 0.63 to 0.96; interaction P value 0.52), and with versus without AS (HR 0.44, 95% CI 0.17 to 1.13 vs HR 0.79, 95% CI 0.64 to 0.97; interaction P value 0.19). For each of the primary and secondary efficacy and safety outcomes, there was no evidence of a different effect of apixaban over warfarin in patients with any VHD subcategory. CONCLUSIONS: In anticoagulated patients with AF, AS is associated with a higher risk of stroke/systemic embolism, bleeding and death. The efficacy and safety benefits of apixaban compared with warfarin were consistent, regardless of presence of MR, AR or AS. CLINICAL TRIAL REGISTRATION: ARISTOTLE clinical trial number NCT00412984.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 12
- $a aortální chlopeň $7 D001021
- 650 _2
- $a fibrilace síní $x komplikace $7 D001281
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nemoci srdečních chlopní $x komplikace $7 D006349
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a mitrální chlopeň $7 D008943
- 650 _2
- $a pyrazoly $x terapeutické užití $7 D011720
- 650 _2
- $a pyridony $x terapeutické užití $7 D011728
- 650 _2
- $a cévní mozková příhoda $x epidemiologie $x prevence a kontrola $7 D020521
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a warfarin $x terapeutické užití $7 D014859
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Wang, Alice $u Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- 700 1_
- $a Mulder, Hillary $u Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- 700 1_
- $a Lopes, Renato D $u Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- 700 1_
- $a Jansky, Petr $u University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Lewis, Basil S $u Lady Davis Carmel Medical Center, Haifa, Israel.
- 700 1_
- $a Gersh, Bernard J $u Mayo Clinic, Rochester, Minnesota, USA.
- 700 1_
- $a Avezum, Alvaro $u Dante Pazzanese Institute, São Paulo University, São Paulo, Brazil.
- 700 1_
- $a Hanna, Michael $u Bristol-Myers Squibb, Princeton, New Jersey, USA.
- 700 1_
- $a Held, Claes $u Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Wallentin, Lars $u Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Granger, Christopher B $u Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- 700 1_
- $a Alexander, John H $u Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- 773 0_
- $w MED00002003 $t Heart (British Cardiac Society) $x 1468-201X $g Roč. 104, č. 15 (2018), s. 1292-1299
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29352007 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411133339 $b ABA008
- 999 __
- $a ok $b bmc $g 1392212 $s 1051207
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 104 $c 15 $d 1292-1299 $e 20180119 $i 1468-201X $m Heart $n Heart $x MED00002003
- LZP __
- $a Pubmed-20190405
